ASP Isotopes acquisition of Renergen approved by 99.8% of Renergen shareholders

ASP Isotopes Inc.

Renergen shareholders voted 99.80% in favor of scheme of arrangement for acquisition by ASP Isotopes.
Transaction remains subject to regulatory approvals and third-party consents; expected effective Q3 2025.
Combined entity targets over $300M EBITDA by 2030 from isotopes, helium, and LNG sales.
Deal expected to be highly accretive to ASP Isotopes revenue, EBITDA, EPS, and cash flow from 2026.
Combination aims to create global leader in critical materials including helium and isotopically enriched gases.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.